[併発症を超えて: CAR-Tは,二次DLBCLの弱い患者の安全で効果的な選択肢である
1Uoc Ematologia e Trapianto di Cellule Staminali Emopoietiche, Dipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli Irccs, Roma.
Recenti progressi in medicina
|February 20, 2026
まとめ
CD19 CAR-T治療は,分散型大B細胞リンパ腫 (DLBCL) の弱い患者にとって安全である可能性があります. この症例報告は,管理可能な毒性を持つ74歳の患者が寛解を達成し,排除基準に異議を唱えていることを示しています.
科学分野:
- 腫瘍学 腫瘍学
- 免疫療法による免疫療法です.
- 血液学 ヘマトロジ
背景:
- CD19 CAR-T治療は,再発/耐性不全の拡散型大B細胞リンパ腫 (DLBCL) の標準的なセカンドライン治療である.
- CAR-T療法を受けているDLBCLの弱い患者の管理は,毒性および非再発死亡リスクのために議論されています.
研究 の 目的:
- 高リスクDLBCLの弱い高齢患者におけるアキシカバテゲン・シロレウセルの安全性と有効性を評価する.
- CAR-T療法における毒性のダイナミックパラメータと比較した併発性スコアの予測価値を評価する.
主な方法:
- 耐火性DLBCLと複数の併発性疾患を患った74歳の男性に関する症例報告.
- サイトカイン放出症候群 (CRS) とサイトペニアを含む有害事象のモニタリング.
- 患者リスクの評価は,ベースライン併発性指数 (CIRS,HCT-CI) とダイナミックパラメータ (ECOG,MEASIX,CAR-HEMATOTOX) を用いたものです.
主要な成果:
- 患者は治療後14ヶ月で持続的な完全寛解を達成しました.
- 高いベースライン併発性スコアにもかかわらず,患者はグレード1のCRSのみを経験し,トシリズマブと一時的なサイトペニアで成功裏に管理されました.
- 併発症だけでは重度の毒性を予測できず,ALYCANTEと現実世界のコホートからの発見と一致しました.
結論:
- DLBCLの弱い患者はCD19 CAR-T療法に耐えて,持続的な寛解を達成することができます.
- ダイナミックな臨床パラメータ (ECOG,mEASIX,CAR-HEMATOTOX) は,重度の毒性のリスクのある患者を特定する上で,静的な併発性スコアよりも効果的です.
- 高齢者または併発性疾患の患者の事前排除は,潜在的に治療的なCAR-T治療へのアクセスを制限する可能性があります.
さらに関連する動画
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.0K
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
1.5K
関連する概念動画
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
